Bioinformatica-Bioestadistica.-Virus Breve resumen
El virus no es un organismo vivo, sino una molecula de proteina (ADN) cubierta por una capa protectora de lipido (grasa), que al ser absorbida por las celulas de las mucosas ocular, nasal o bucal, cambian el codigo genetico de ellas (mutacion) y las convierten en celulas agresoras y multiplicadoras.
* Como el virus no es un organismo vivo sino una molecula de proteina, no se le mata, sino que se desintegra solo. El tiempo de desintegracion depende de la temperatura, humedad y tipo de material donde reposa.
* El virus es muy fragil, lo unico que lo protege es una capa fina externa de grasa. Por eso es que cualquier jabon o detergente es el mejor remedio, porque la espuma CORTA la GRASA (por eso es que hay que frotarse tanto por 20 segs o mas, para hacer mucha espuma). Al disolver la capa de grasa, la molecula de proteina se dispersa y desintegra sola.
El virus es natural y no ha
estado manipulado. Cuando manipula un virus, manipulats su ADN y los
lugares donde se hizo la manipulación se ve, es como notar las
"cicatrices" de un corta y pega.
En construccion....
1. -Documentos técnicos para profesionales
- Rider TH, Zook CE, Boettcher TL, Wick ST, Pancoast JS, Zusman BD (2011). «(en inglés): Broad-spectrum antiviral therapeutics Terapias antivirales de espectro amplio». PLoS ONE 6 (7): e22572. PMC 3144912. PMID 21818340. doi:10.1371/journal.pone.0022572.
- Fiona Macrae (11 de agosto de 2011), «(en inglés): Greatest discovery since penicillin: A cure for everything - from colds to HIV Mejor discubrimiento desde la penicilina: Una cura para todo - de resfriados al VIH», The Daily Mail (UK)
Influenza A - Castor canadensis (American beaver)
Comentario: Creo que el animal 0 puede ser un castor, más que un pangolin.
5-Imperial College
https://foro.coronavirusmakers.org/index.php?p=/discussion/288/app-para-control-de-distancia-segura-social
https://foro.coronavirusmakers.org/index.php?p=/discussion/559/trazabilidad-coronavirus-antes-y-despues-gps-on-en-tu-disopositivo-movil-geofencing
- http://safepaths.mit.edu/ (MIT)
- https://covid-watch.org/collaborate (Standford)
- https://covid-19-track.com/stats/main (covid-19 tracker)
7- Ponencia del doctor J.M Miro
.
Incubacion: Periodo medio es de 5 dias, oscila entre 2 y 14 dias
Diagnostico: Un 80 % seran casos leves, un 10 % de los pacietes leves a severos, y de estos severos un 15-20 % de severos a criticos. De forma muy rapida entre 7 a 14 dias.
La carga viral es mas elevada en el momento del diagnostico, en la primera semana de los sintomas
- En dos semanas despues hemos pasado de 300.000 a 1.000.0000 de casos, de 120 a 180 paises
-En la actualidad EEUU lidera los casos es el pais que tiene mas casos, seguido de España y de Italia (en proporcion a los habitantes ahora es España,166.000, con 62.000 altas)
-La Mortalidad global es del 5 %, en España e Italia el 10 %,Es intersante con Alemania con 80.000 con una mortalidad muy baja de 1,2 %
-
- Estudio New England -Transmisión por gotas, de 1 a 2 metros, los investigadores publicaron estudio puede persistir unas horas en el aire y varios dias en superfies, por esta cuestión del tema de aerosoles los sanitarios deben protegerse bien con el material adecuado.
-Los antivirales hay que darlos pronto
-Los datos actuales indican que en los pacientes criticos la mortalidad es del 50 %
-Nos explica las novedades, indica que se han realizado 250 estudios en marcha, con 157 ensayos clinicos (redesivir, colorofila,la hydroxycholoquine, y acitominicina,rendisivir,etc)
-Posible reactivacion de la hepatitis C en tratamientos largos
-En la actualidad hay 30 estudios con vacunas
**Actualización sobre la situación de la COVID-19 | Dr. Josep Maria Miró - 03/abril/2020
Cómo PROTEGERSE del CORONAVIRUS SARS-Cov-2 (Covid-19)
https://www.youtube.com/watch?v=p8xYmZbEtJI
MODELIZACIÓN EPIDEMIOLÓGICA DEL COVID-19
- https://covid19.webs.upv.es/
Social Distancing to Slow the Coronavirus
-https://towardsdatascience.com/social-distancing-to-slow-the-coronavirus-768292f04296
DATOS ESPAÑA POR COMUNIDADES COVID-19
- https://github.com/victorvicpal/COVID19_es/blob/master/data/final_data/dataCOVID19_es.csv
DENSIDADES POBLACIÓN, COMUNIDADES AUTÓNOMAS, covid19- ALTAS, MASCARILLAS,EDAD
https://github.com/datadista/datasets/tree/master/COVID%2019
INFORMES COVID Mujeres/hombres/edades/enfermedades
https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx
-DATOS MUNDIALES
DENSIDADES DE POBLACIÓN, Y DATOS COVID19 JSON aCTUALIZADOS
https://github.com/JoseCarlosGarcia95/covid-api-datasource/tree/master/data
DATOS COMPILADOS POR LA UNIVERSIDAD Johns Hopkins University CenteR
https://data.humdata.org/dataset/novel-coronavirus-2019-ncov-cases
DENSIDADES DE POBLACIÓN
https://worldpopulationreview.com/countries/
Bibliografia
-Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome. 23 de enero de 2020 [citado 7 de febrero de 2020]; Disponible en: http://www.ncbi.nlm.nih.gov/nuccore/MN908947
-Novel Coronavirus (2019-nCoV) situation reports [Internet]. [citado 23 de enero de 2020]. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
-- Paules CI, Marston HD, Fauci AS. Coronavirus Infections—More Than Just the Common Cold. JAMA [Internet]. 23 de enero de 2020 [citado 6 de febrero de 2020]; Disponible en: https://jamanetwork.com/journals/jama/fullarticle/27598154
. World health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. 2020. Disponible en: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf5
Cyranoski D. Mystery deepens over animal sourceof coronavirus. Nature. marzo de 2020;579(7797):18-9. 6. Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-92.
Saif LJ. Animal coronavirus: lessons for SARS [Internet]. National Academies Press (US); 2004 [citado 6 de febrero de 2020]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK92442/8
Hung LS. The SARS epidemic in Hong Kong: what lessons have we learned? J R Soc Med [Internet]. agosto de 2003 [citado 6 de febrero de 2020];96(8):374-8. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC539564/9
To KK-W, Tsang OT-Y, Chik-Yan Yip C, Chan K-H, Wu T-C, Chan JMC, etal. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis Off Publ Infect Dis Soc Am. 12 defebrero de 2020; 10. Doremalen N van, Bushmaker T, Morris D, Holbrook M, Gamble A, Williamson B, etal. Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1.NEJM. https://www.nejm.org/doi/full/10.1056/NEJMc2004973?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed11
. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect. 6 de febrero de 2020; 12. World health Organization. Water, sanitation, hygiene and waste management for COVID-19 [Internet]. 2020. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/331305/WHO-2019-NcOV-IPC_WASH-2020.1-eng.pdf?sequence=1&isAllowed=y13
. Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, etal. Aerodynamic Characteristics and RNA Concentration of SARS-CoV-2 Aerosol in Wuhan Hospitals during COVID-19 Outbreak. bioRxiv [Internet]. 10 de marzo de 2020 [citado 25 de marzo de 2020];2020.03.08.982637. Disponible en: https://www.biorxiv.org/content/10.1101/2020.03.08.982637v1Información científica-técnica
. Enfermedad por coronavirus, COVID-1926 de marzo de 20202214. Booth TF, Kournikakis B, Bastien N, Ho J, Kobasa D, Stadnyk L,etal. Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis. 1 de mayo de 2005;191(9):1472-7. 15.
Yu ITS, Wong TW, Chiu YL, Lee N, Li Y. Temporal-spatial analysisof severe acute respiratory syndrome among hospital inpatients. Clin Infect Dis Off Publ Infect Dis Soc Am. 1 de mayo de 2005;40(9):1237-43. 16. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol. 19 de febrero de 2020; 17.
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, etal. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med [Internet]. 31 de enero de 2020 [citado 6 de febrero de 2020];0(0):null. Disponible en: https://doi.org/10.1056/NEJMoa200119118
. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, etal. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet Lond Engl. 30 de enero de 2020; 19. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, etal. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet [Internet]. 12 de febrero de 2020 [citado 13 de febrero de 2020];0(0). Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30360-3/abstract20
. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, etal. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med [Internet]. 28 de febrero de 2020 [citado 6 de marzo de 2020]; Disponible en: https://www.nejm.org/doi/10.1056/NEJMoa200203221
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, etal. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med [Internet]. 29 de enero de 2020 [citado 6 de febrero de 2020]; Disponible en: https://doi.org/10.1056/NEJMoa200131622.
Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet [Internet]. 31 de enero de 2020 [citado 6 de febrero de 2020];0(0). Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30260-9/abstract23
. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Eurosurveillance [Internet]. 30 de enero de 2020 [citado 6 de febrero de 2020];25(4):2000058. Disponible en: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.4.200005824
. Huang LL, Shen SP, Yu P, Wei YY. [Dynamic basic reproduction number based evaluation for current prevention and control of COVID-19 outbreak in China]. Zhonghua Liu Xing Bing Xue Za Zhi Zhonghua Liuxingbingxue Zazhi. 1 de marzo de 2020;41(4):466-9. 25. Zhang S, Diao M, Yu W, Pei L, Lin Z, Chen D. Estimation of the reproductive number of Novel Coronavirus (COVID-19) andthe probable outbreak size on the Diamond Princess cruise ship: A data-driven analysis. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 22 de febrero de 2020; Información científica-técnica. Enfermedad por coronavirus, COVID-1926 de marzo de 20202326.
Burke RM. Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 —United States, January–February 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020 [citado 4 de marzo de 2020];69. Disponible en: https://www.cdc.gov/mmwr/volumes/69/wr/mm6909e1.htm27
. Liu Y, Eggo RM, Kucharski AJ. Secondary attack rate and superspreading events for SARS-CoV-2. Lancet Lond Engl. 27 de febrero de 2020; 28. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, etal. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 7 de febrero de 2020; 29. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, etal. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med [Internet]. 30 de enero de 2020 [citado 4 de febrero de 2020];0(0):null. Disponible en: https://doi.org/10.1056/NEJMc200146830.
Kai Kupferschmidt. Study claiming new coronavirus can be transmitted by people without symptoms was flawed. Science [Internet]. 3 de febrero de 2020; Disponible en: https://www.sciencemag.org/news/2020/02/paper-non-symptomatic-patient-transmitting-coronavirus-wrong31
. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, etal. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet Lond Engl. 24 de enero de 2020; 32. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, etal. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 19 de febrero de 2020; 33. Huang R, Xia J, ChenY, Shan C, Wu C. A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China. Lancet Infect Dis. 28 de febrero de 2020; 34. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, etal. Presumed Asymptomatic Carrier Transmission of COVID-19.JAMA [Internet]. 21 de febrero de 2020 [citado 6 de marzo de 2020]; Disponible en: https://jamanetwork.com/journals/jama/fullarticle/276202835
. Tong Z-D, Tang A, Li K-F, Li P, Wang H-L, Yi J-P, etal. Potential Presymptomatic Transmission of SARS-CoV-2,Zhejiang Province, China. Emerg Infect Dis [Internet]. 2020 [citado 17 de marzo de 2020];26. Disponible en: https://wwwnc.cdc.gov/eid/article/26/5/20-0198_article36
Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? The Lancet [Internet]. 9 de marzo de 2020 [citado 17 de marzo de 2020];0(0). Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)305675/abstract37
. Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, etal. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Health. 28 de febrero de 2020; 38. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques | bioRxiv [Internet]. [citado 25 de marzo de 2020]. Disponible en: https://www.biorxiv.org/content/10.1101/2020.03.13.990226v139.
Ganyani T, Kremer C, Chen D, Torneri A, Faes C, Wallinga J, etal. Estimating the generation interval for COVID-19 based on symptom onset data. medRxiv [Internet]. 8 de marzo de 2020 [citado 17 de marzo de 2020];2020.03.05.20031815. Disponible en: https://www.medrxiv.org/content/10.1101/2020.03.05.20031815v1I
Información científica-técnica. Enfermedad por coronavirus, COVID-1926 de marzo de 20202440. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 24 de febrero de 2020; 41. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study -The Lancet Infectious Diseases [Internet]. [citado 25 de marzo de 2020]. Disponible en: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30196-1/fulltext42
. Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, Liu J-M, etal. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 19 de marzo de 2020; 43. Xing Y, Mo P, Xiao Y, Zhao O, Zhang Y, Wang F. Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020. Eurosurveillance [Internet]. 12 de marzo de 2020 [citado 25 de marzo de 2020];25(10):2000191. Disponible en: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.200019144.
Positive RT-PCR Test Results in Patients Recovered From COVID-19 | Global Health | JAMA | JAMA Network [Internet]. [citado 25 de marzo de 2020]. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/276245245
. Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2 | bioRxiv [Internet]. [citado 25 de marzo de 2020]. Disponible en: https://www.biorxiv.org/content/10.1101/2020.03.21.001628v146. The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice | bioRxiv [Internet]. [citado 25 de marzo de 2020]. Disponible en: https://www.biorxiv.org/content/10.1101/2020.02.07.939389v347
. Characterization of anti-viral immunity in recovered individuals infected by SARS-CoV-2 | medRxiv [Internet]. [citado 25 de marzo de 2020]. Disponible en: https://www.medrxiv.org/content/10.1101/2020.03.17.20036640v148.
Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice | medRxiv [Internet]. [citado 25 de marzo de 2020]. Disponible en: https://www.medrxiv.org/content/10.1101/2020.03.18.20038018v1.external-links.html49.
Red Nacional de Vigilancia Epidemiológica. Informe sobre la situación de COVID-19 en España [Internet]. Centro Nacional de Epidemiología; 2020 mar. Report No.: 14. Disponible en: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20n%C2%BA%2014.%20Situaci%C3%B3n%20de%20COVID-19%20en%20Espa%C3%B1a%20a%2024%20marzo%20de%202020.pdf50.
Clinical characteristics of 2019 novel coronavirus infection in China [Internet]. [citado 11 de febrero de 2020]. Disponible en: https://www.medrxiv.org/content/10.1101/2020.02.06.20020974v151
. Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate -a word of caution. Swiss Med Wkly. 27 de enero de 2020;150:w20203. 52. Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK –seventh update [Internet]. European Center for Disease Control and Prevention; 2020 mar. Información científica-técnica. Enfermedad por coronavirus, COVID-1926 de marzo de 202025Disponible en: https://www.ecdc.europa.eu/sites/default/files/documents/RRA-seventh-update-Outbreak-of-coronavirus-disease-COVID-19.pdf53
Wu P, Hao X, Lau EHY, Wong JY, Leung KSM, Wu JT, etal. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. enero de 2020;25(3). 54. Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. JAMA. 23 de enero de 2020; 55. Galanti M, Birger R, Ud-Dean M, Filip I, Morita H, Comito D, etal. Longitudinal active sampling for respiratory viral infections across age groups. Influenza Other Respir Viruses. 2019;13(3):226-32. 56.
Killerby ME, Biggs HM, Haynes A, Dahl RM, Mustaquim D, Gerber SI, etal. Human coronavirus circulation in the United States 2014-2017. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2018;101:52-6. 57. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, etal. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet Lond Engl. 30 de enero de 2020; 58. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, etal. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B [Internet]. 27 de febrero de 2020 [citado 5 de marzo de 2020]; Disponible en: http://www.sciencedirect.com/science/article/pii/S221138352030299959
. Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol [Internet]. 1 de abril de 2020 [citado 7 de febrero de 2020];79:104212. Disponible en: http://www.sciencedirect.com/science/article/pii/S156713482030044760.
Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging in China -Key Questions for Impact Assessment. N Engl J Med. 24 de enero de 2020; 61. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, etal. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 3 de febrero de 2020; 62. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science [Internet]. 4 de marzo de 2020 [citado 5 de marzo de 2020]; Disponible en: https://science.sciencemag.org/content/early/2020/03/03/science.abb276263
. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, etal. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science [Internet]. 19 de febrero de 2020 [citado 5 de marzo de 2020]; Disponible en: https://science.sciencemag.org/content/early/2020/02/19/science.abb250764.
Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2 | bioRxiv [Internet]. [citado 25 de marzo de 2020]. Disponible en: https://www.biorxiv.org/content/10.1101/2020.03.11.987222v165.
Tikellis C, Thomas MC. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int J Pept. 2012;2012:256294. Información científica-técnica. Enfermedad por coronavirus, COVID-1926 de marzo de 20202666. Garabelli PJ, Modrall JG, Penninger JM, Ferrario CM, Chappell MC. Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Exp Physiol. mayode 2008;93(5):613-21. 67. Stewart JA, Lazartigues E, Lucchesi PA. The angiotensin converting enzyme 2/Ang-(1-7) axis in the heart: a role for MAS communication? Circ Res. 21 de noviembre de 2008;103(11):1197-9. 68.
Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, etal. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail. septiembre de 2009;2(5):446-55. 69. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, etal. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 7 de julio de 2005;436(7047):112-6. 70. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, etal. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. marzo de 2020;63(3):364-74. 71. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, etal. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 27 de noviembre de 2003;426(6965):450-4. 72.
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, etal. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. agosto de 2005;11(8):875-9. 73. Wang J, Tang K, Feng K, Lv W. High Temperature and High Humidity Reduce the Transmission of COVID-19 [Internet]. Rochester, NY: Social Science Research Network; 2020 mar [citado 25 de marzo de 2020]. Report No.: ID 3551767. Disponible en: https://papers.ssrn.com/abstract=355176774
. Sajadi MM, Habibzadeh P, Vintzileos A, Shokouhi S, Miralles-Wilhelm F, Amoroso A. Temperature, Humidity and Latitude Analysis to Predict Potential Spread and Seasonality for COVID-19 [Internet]. Rochester, NY: Social Science Research Network; 2020 mar [citado 25 de marzo de 2020]. Report No.: ID 3550308. Disponible en: https://papers.ssrn.com/abstract=356062175. Seasonality of SARS-CoV-2: Will COVID-19 go away on its own in warmer weather?
–Center for Communicable Disease Dynamics [Internet]. [citado 25 de marzo de 2020]. Disponible en: https://ccdd.hsph.harvard.edu/will-covid-19-go-away-on-its-own-in-warmer-weather/76
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19). China CDC Wkly [Internet]. febrero de 2020; Disponible en: http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f5177. Pan X, Chen D, Xia Y, Wu X, Li T, Ou X, etal. Asymptomatic casesin a family cluster with SARS-CoV-2 infection. Lancet Infect Dis. 19 de febrero de 2020; 78. Field Briefing: Diamond Princess COVID-19 Cases, 20 Feb Update [Internet]. [citado 4 de marzo de 2020]. Disponible en: https://www.niid.go.jp/niid/en/2019-ncov-e/9417-covid-dp-fe-02.html79.
Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance [Internet]. 12 de marzo de 2020 [citado 16 de marzo de 2020];25(10):2000180. Disponible en: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.2000180
Información científica-técnica. Enfermedad por coronavirus, COVID-1926 de marzo de 20202780. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, etal. Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened among Close Contacts in Nanjing, China. medRxiv [Internet]. 25 de febrero de 2020 [citado 6 de marzo de 2020];2020.02.20.20025619. Disponible en: https://www.medrxiv.org/content/10.1101/2020.02.20.20025619v281
Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study | medRxiv [Internet]. [citado 25 de marzo de 2020]. Disponible en: https://www.medrxiv.org/content/10.1101/2020.02.22.20026500v182
. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol [Internet]. 5 de marzo de 2020 [citado 16 de marzo de 2020];1-2. Disponible en: https://www.nature.com/articles/s41569-020-0360-583. Ocular manifestations and clinical characteristics of 534 cases of COVID-19 in China: A cross-sectional study | medRxiv [Internet]. [citado 25 de marzo de 2020]. Disponible en: https://www.medrxiv.org/content/10.1101/2020.03.12.20034678v184
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, etal. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med [Internet]. 24 de febrero de 2020 [citado 6 de marzo de 2020];0(0). Disponible en: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30079-5/abstract85
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, etal. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Lond Engl. 24 de enero de 2020; 86. Informe sobre la situación de COVID-19 en España. CNE. SiVies. CNM (ISCIII); 2020 mar. 87. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, etal. Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts. medRxiv [Internet]. 4 de marzo de 2020 [citado 17 de marzo de 2020];2020.03.03.20028423. Disponible en: https://www.medrxiv.org/content/10.1101/2020.03.03.20028423v188
- Cai JH, Wang XS, Ge YL, Xia AM, Chang HL, Tian H, etal. [First case of 2019 novel coronavirus infection in children in Shanghai]. Zhonghua Er Ke Za Zhi Chin J Pediatr. 4 de febrero de 2020;58(0):E002. 89. Kam K-Q, Yung CF, Cui L, Lin Tzer Pin R, Mak TM, Maiwald M, etal. A Well Infant with Coronavirus Disease 2019 (COVID-19)with High Viral Load. Clin Infect Dis Off Publ Infect Dis Soc Am. 28 de febrero de 2020; 90. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, etal. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond Engl. 11 de marzo de 2020; 91. Ferrario Carlos M., Jessup Jewell, Chappell Mark C., Averill David B., Brosnihan K. Bridget, Tallant E. Ann, etal. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2. Circulation [Internet]. 24 de mayo de 2005 [citado 17 de marzo de 2020];111(20):2605-10. Disponible en: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.104.51046192
- Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. [Internet]. undefined. 2004 [citado 16 de marzo de 2020]. Disponible en: Información científica-técnica. Enfermedad por coronavirus, COVID-1926 de marzo de 202028/paper/The-central-role-of-angiotensin-I-converting-enzyme-Moskowitz-Johnson/11ad6b23adfb8f141983dccc9883ff6de060b2cd93
- WONG CK, LAM CWK, WU AKL, IP WK, LEE NLS, CHAN IHS, etal. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol [Internet]. abril de 2004;136(1):95-103. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808997/94
. Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, etal. Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection. Sci Rep [Internet]. 22 de agosto de 2017 [citado 16 de marzo de 2020];7(1):1-12. Disponible en: https://www.nature.com/articles/s41598-017-09536-z95. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 11 de marzo de 2020; 96. Soro-Paavonen A, Gordin D, Forsblom C, Rosengard-Barlund M, Waden J, Thorn L, etal. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens. febrero de 2012;30(2):375-83. 97. Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. -PubMed -NCBI [Internet]. [citado 25 de marzo de 2020]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/2432956498
. Zhang W, Xu Y-Z, Liu B, Wu R, Yang Y-Y, Xiao X-Q, etal
Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. ScientificWorldJournal. 2014;2014:603409.
99. Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. -PubMed -NCBI [Internet]. [citado 25 de marzo de 2020]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/?term=Rosiglitazone+treatment+of+type+2+diabetic+db%2Fdb+mice+attenuates+urinary+albumin+and+angiotensin+converting+enzyme+2+excretion100
Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia -Zhu -Translational Pediatrics [Internet]. [citado 6 de marzo de 2020]. Disponible en: http://tp.amegroups.com/article/view/35919/28274101. Honda-Okubo Y, Barnard D, Ong CH, Peng B-H, Tseng C-TK, Petrovsky N. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. marzo de 2015;89(6):2995-3007. 102.
Deng Y, Lan J, Bao L, Huang B, Ye F, Chen Y, etal. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect. 4 de abril de 2018;7(1):60. 103. Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, etal. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. septiembre de 2019;19(9):1013-22. 104. Lin J-T, Zhang J-S, Su N, Xu J-G, Wang N, Chen J-T, etal. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratorysyndrome coronavirus vaccine.
Antivir Ther. 2007;12(7):1107-13. Información científica-técnica. Enfermedad por coronavirus, COVID-1926 de marzo de 202029105. Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, etal. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 25 de noviembre de 2008;26(50):6338-43. 106. Matz KM, Marzi A, Feldmann H. Ebola vaccine trials: progress in vaccine safety and immunogenicity. Expert Rev Vaccines. diciembre de 2019;18(12):1229-42. 107. Agencia Europea del Medicamento (EMA). ERVEBBO. Ficha técnica o resumen de las características del producto [Internet]. Disponible en: https://www.ema.europa.eu/en/documents/product-information/ervebo-epar-product-information_es.pdf108
.
-. World health Organization. R&D Blueprint [Internet]. Disponible en: https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/.109. The Coalition for Epidemic Preparedness Innovations (CEPI). [Internet]. Disponible en: https://cepi.net/110
. Wang Q, Zhang L, Kuwahara K, LiL, Liu Z, Li T, etal. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infect Dis. 13 de 2016;2(5):361-76. 111. Agrawal AS, Tao X, Algaissi A, Garron T, Narayanan K, Peng B-H, etal. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccines Immunother. 2016;12(9):2351-6. 112. Tseng C-T, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, etal. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS One. 2012;7(4):e35421. 113.
Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, etal. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.
-
J Virol. diciembre de 2011;85(23):12201-15. 114. Polack FP. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr Res. julio de 2007;62(1):111-5. 115. Tseng C-TK, Huang C, Newman P, Wang N, Narayanan K, Watts DM, etal. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J Virol. febrero de 2007;81(3):1162-73
No hay comentarios:
Publicar un comentario